These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 3578325)

  • 21. Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics.
    Nix DE; Cumbo TJ; Kuritzky P; DeVito JM; Schentag JJ
    Am J Med; 1987 Apr; 82(4A):146-53. PubMed ID: 3555029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The pharmacokinetics of ciprofloxacin in patients with renal function of various degrees].
    Yu H; Wang HY; Sun ZM
    Zhonghua Nei Ke Za Zhi; 1994 Jul; 33(7):449-51. PubMed ID: 7867438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ciprofloxacin concentrations in human fluids and tissues following a single oral dose.
    Esposito S; Galante D; Barba D; D'Errico G; Mazzone A; Montanaro S
    Int J Clin Pharmacol Res; 1987; 7(3):181-6. PubMed ID: 3596861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function.
    Bergan T; Thorsteinsson SB; Rohwedder R; Scholl H
    Chemotherapy; 1989; 35(6):393-405. PubMed ID: 2612228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dosage regimen of ranitidine in patients with renal impairment.
    Ebihara A; Ohashi K; Ikeda T; Yuhara M; Tagawa H; Yamakado M; Asano Y; Tabei K; Nakazawa K; Kondo K
    Int J Clin Pharmacol Res; 1989; 9(1):1-7. PubMed ID: 2707920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transintestinal elimination of ciprofloxacin.
    Rohwedder R; Bergan T; Thorsteinsson SB; Scholl H
    Chemotherapy; 1990; 36(2):77-84. PubMed ID: 2311444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis.
    Stutman HR; Shalit I; Marks MI; Greenwood R; Chartrand SA; Hilman BC
    Am J Med; 1987 Apr; 82(4A):142-5. PubMed ID: 3555028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacology of orally administered ciprofloxacin.
    Brittain DC; Scully BE; McElrath MJ; Steinman R; Labthavikul P; Neu HC
    Drugs Exp Clin Res; 1985; 11(5):339-41. PubMed ID: 2941262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
    Shah A; Lettieri J; Blum R; Millikin S; Sica D; Heller AH
    J Antimicrob Chemother; 1996 Jul; 38(1):103-16. PubMed ID: 8858462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal handling of zomepirac sodium (McN-2783-21-98) in the rat.
    O'Neill PJ; Yorgey KA; Migdalof BH; Gussin RZ
    J Pharmacol Exp Ther; 1979 Jun; 209(3):366-70. PubMed ID: 35605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers.
    Gonzalez MA; Moranchel AH; Duran S; Pichardo A; Magana JL; Painter B; Forrest A; Drusano GL
    Antimicrob Agents Chemother; 1985 Aug; 28(2):235-9. PubMed ID: 2939794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the interaction of lithium and alprazolam.
    Evans RL; Nelson MV; Melethil S; Townsend R; Hornstra RK; Smith RB
    J Clin Psychopharmacol; 1990 Oct; 10(5):355-9. PubMed ID: 2124219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function.
    Gasser TC; Ebert SC; Graversen PH; Madsen PO
    Antimicrob Agents Chemother; 1987 May; 31(5):709-12. PubMed ID: 3300537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of cefepime in subjects with renal insufficiency.
    Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA
    Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of ciprofloxacin in cystic fibrosis.
    Davis RL; Koup JR; Williams-Warren J; Weber A; Heggen L; Stempel D; Smith AL
    Antimicrob Agents Chemother; 1987 Jun; 31(6):915-9. PubMed ID: 3619423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of Ro 23-6240 (AM 833), a new trifluorinated quinolone.
    Weidekamm E; Stöckel K; Dell D
    Chemioterapia; 1987 Jun; 6(2 Suppl):307-8. PubMed ID: 3151346
    [No Abstract]   [Full Text] [Related]  

  • 37. Absolute oral bioavailability of ciprofloxacin.
    Drusano GL; Standiford HC; Plaisance K; Forrest A; Leslie J; Caldwell J
    Antimicrob Agents Chemother; 1986 Sep; 30(3):444-6. PubMed ID: 3777908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose ranging study and constant infusion evaluation of ciprofloxacin.
    Drusano GL; Plaisance KI; Forrest A; Standiford HC
    Antimicrob Agents Chemother; 1986 Sep; 30(3):440-3. PubMed ID: 3777907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal handling of fleroxacin in rabbits, dogs, and humans.
    Shiba K; Saito A; Shimada J; Hori S; Kaji M; Miyahara T; Kusajima H; Kaneko S; Saito S; Ooie T
    Antimicrob Agents Chemother; 1990 Jan; 34(1):58-64. PubMed ID: 2109576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis.
    Singlas E; Taburet AM; Landru I; Albin H; Ryckelinck JP
    Eur J Clin Pharmacol; 1987; 31(5):589-93. PubMed ID: 3830244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.